Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α

Hiroki Mitoma, Takahiko Horiuchi, Nobuaki Hatta, Hiroshi Tsukamoto, Shin Ichi Harashima, Yuji Kikuchi, Junji Otsuka, Seiichi Okamura, Shigeru Fujita, Mine Harada

研究成果: ジャーナルへの寄稿記事

217 引用 (Scopus)

抄録

Background & Aims: Both infliximab (chimeric anti-tumor necrosis factor [TNF]-α antibody) and etanercept (p75 TNF-α receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease. To clarify this difference in clinical efficacy, we investigated reverse signaling through transmembrane TNF-α (mTNF) by these 2 anti-TNF agents. Methods: We stably transfected wild-type and cytoplasmic serine-replaced mutant forms of mTNF in human Jurkat T cells. Cells were stimulated with infliximab and etanercept and then analyzed for E-selectin expression, reactive oxygen species accumulation, apoptosis, and cell cycle distribution by flow cytometry. Interleukin-10 and interferon-γ were measured by enzyme-linked immunosorbent assay. Phospho-c-Jun NH2-terminal kinase, Bax, Bak, p21WAF1/CIP1, caspase-8, and caspase-3 were examined by immunoblotting. Results: Both anti-TNF agents induced E-selectin expression, but only infliximab induced interleukin-10 production, apoptosis, and G0/G1 cell cycle arrest. Apoptosis and cell cycle arrest were abolished by substitution of all 3 cytoplasmic serine residues of mTNF by alanine residues. Infliximab induced accumulation of reactive oxygen species and up-regulation of Bax, Bak, and p21WAF1/CIP1 proteins, suggesting the involvement of p53 activation. Moreover, phosphorylation of c-Jun NH2-terminal kinase was necessary for infliximab-induced apoptosis and cell cycle arrest. Conclusions: We revealed the mTNF motifs and the downstream intracellular molecular events essential for reverse signaling through mTNF. The biologic effects of mTNF elicited by infliximab should be important action mechanisms of this potent anti-inflammatory agent in addition to the neutralization of soluble TNF-α. These observations will provide insight into the novel role of mTNF in inflammation.

元の言語英語
ページ(範囲)376-392
ページ数17
ジャーナルGastroenterology
128
発行部数2
DOI
出版物ステータス出版済み - 1 1 2005

Fingerprint

Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Apoptosis
E-Selectin
JNK Mitogen-Activated Protein Kinases
Cell Cycle Checkpoints
Interleukin-10
Serine
Reactive Oxygen Species
G1 Phase Cell Cycle Checkpoints
Jurkat Cells
Caspase 8
Tumor Necrosis Factor Receptors
Infliximab
Immunoblotting
Crohn Disease
Caspase 3
Alanine
Interferons
Rheumatoid Arthritis

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

これを引用

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. / Mitoma, Hiroki; Horiuchi, Takahiko; Hatta, Nobuaki; Tsukamoto, Hiroshi; Harashima, Shin Ichi; Kikuchi, Yuji; Otsuka, Junji; Okamura, Seiichi; Fujita, Shigeru; Harada, Mine.

:: Gastroenterology, 巻 128, 番号 2, 01.01.2005, p. 376-392.

研究成果: ジャーナルへの寄稿記事

Mitoma, H, Horiuchi, T, Hatta, N, Tsukamoto, H, Harashima, SI, Kikuchi, Y, Otsuka, J, Okamura, S, Fujita, S & Harada, M 2005, 'Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α', Gastroenterology, 巻. 128, 番号 2, pp. 376-392. https://doi.org/10.1053/j.gastro.2004.11.060
Mitoma, Hiroki ; Horiuchi, Takahiko ; Hatta, Nobuaki ; Tsukamoto, Hiroshi ; Harashima, Shin Ichi ; Kikuchi, Yuji ; Otsuka, Junji ; Okamura, Seiichi ; Fujita, Shigeru ; Harada, Mine. / Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. :: Gastroenterology. 2005 ; 巻 128, 番号 2. pp. 376-392.
@article{1b1d3fe3f94c4f2e84789e8938664839,
title = "Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α",
abstract = "Background & Aims: Both infliximab (chimeric anti-tumor necrosis factor [TNF]-α antibody) and etanercept (p75 TNF-α receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease. To clarify this difference in clinical efficacy, we investigated reverse signaling through transmembrane TNF-α (mTNF) by these 2 anti-TNF agents. Methods: We stably transfected wild-type and cytoplasmic serine-replaced mutant forms of mTNF in human Jurkat T cells. Cells were stimulated with infliximab and etanercept and then analyzed for E-selectin expression, reactive oxygen species accumulation, apoptosis, and cell cycle distribution by flow cytometry. Interleukin-10 and interferon-γ were measured by enzyme-linked immunosorbent assay. Phospho-c-Jun NH2-terminal kinase, Bax, Bak, p21WAF1/CIP1, caspase-8, and caspase-3 were examined by immunoblotting. Results: Both anti-TNF agents induced E-selectin expression, but only infliximab induced interleukin-10 production, apoptosis, and G0/G1 cell cycle arrest. Apoptosis and cell cycle arrest were abolished by substitution of all 3 cytoplasmic serine residues of mTNF by alanine residues. Infliximab induced accumulation of reactive oxygen species and up-regulation of Bax, Bak, and p21WAF1/CIP1 proteins, suggesting the involvement of p53 activation. Moreover, phosphorylation of c-Jun NH2-terminal kinase was necessary for infliximab-induced apoptosis and cell cycle arrest. Conclusions: We revealed the mTNF motifs and the downstream intracellular molecular events essential for reverse signaling through mTNF. The biologic effects of mTNF elicited by infliximab should be important action mechanisms of this potent anti-inflammatory agent in addition to the neutralization of soluble TNF-α. These observations will provide insight into the novel role of mTNF in inflammation.",
author = "Hiroki Mitoma and Takahiko Horiuchi and Nobuaki Hatta and Hiroshi Tsukamoto and Harashima, {Shin Ichi} and Yuji Kikuchi and Junji Otsuka and Seiichi Okamura and Shigeru Fujita and Mine Harada",
year = "2005",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2004.11.060",
language = "English",
volume = "128",
pages = "376--392",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α

AU - Mitoma, Hiroki

AU - Horiuchi, Takahiko

AU - Hatta, Nobuaki

AU - Tsukamoto, Hiroshi

AU - Harashima, Shin Ichi

AU - Kikuchi, Yuji

AU - Otsuka, Junji

AU - Okamura, Seiichi

AU - Fujita, Shigeru

AU - Harada, Mine

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background & Aims: Both infliximab (chimeric anti-tumor necrosis factor [TNF]-α antibody) and etanercept (p75 TNF-α receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease. To clarify this difference in clinical efficacy, we investigated reverse signaling through transmembrane TNF-α (mTNF) by these 2 anti-TNF agents. Methods: We stably transfected wild-type and cytoplasmic serine-replaced mutant forms of mTNF in human Jurkat T cells. Cells were stimulated with infliximab and etanercept and then analyzed for E-selectin expression, reactive oxygen species accumulation, apoptosis, and cell cycle distribution by flow cytometry. Interleukin-10 and interferon-γ were measured by enzyme-linked immunosorbent assay. Phospho-c-Jun NH2-terminal kinase, Bax, Bak, p21WAF1/CIP1, caspase-8, and caspase-3 were examined by immunoblotting. Results: Both anti-TNF agents induced E-selectin expression, but only infliximab induced interleukin-10 production, apoptosis, and G0/G1 cell cycle arrest. Apoptosis and cell cycle arrest were abolished by substitution of all 3 cytoplasmic serine residues of mTNF by alanine residues. Infliximab induced accumulation of reactive oxygen species and up-regulation of Bax, Bak, and p21WAF1/CIP1 proteins, suggesting the involvement of p53 activation. Moreover, phosphorylation of c-Jun NH2-terminal kinase was necessary for infliximab-induced apoptosis and cell cycle arrest. Conclusions: We revealed the mTNF motifs and the downstream intracellular molecular events essential for reverse signaling through mTNF. The biologic effects of mTNF elicited by infliximab should be important action mechanisms of this potent anti-inflammatory agent in addition to the neutralization of soluble TNF-α. These observations will provide insight into the novel role of mTNF in inflammation.

AB - Background & Aims: Both infliximab (chimeric anti-tumor necrosis factor [TNF]-α antibody) and etanercept (p75 TNF-α receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease. To clarify this difference in clinical efficacy, we investigated reverse signaling through transmembrane TNF-α (mTNF) by these 2 anti-TNF agents. Methods: We stably transfected wild-type and cytoplasmic serine-replaced mutant forms of mTNF in human Jurkat T cells. Cells were stimulated with infliximab and etanercept and then analyzed for E-selectin expression, reactive oxygen species accumulation, apoptosis, and cell cycle distribution by flow cytometry. Interleukin-10 and interferon-γ were measured by enzyme-linked immunosorbent assay. Phospho-c-Jun NH2-terminal kinase, Bax, Bak, p21WAF1/CIP1, caspase-8, and caspase-3 were examined by immunoblotting. Results: Both anti-TNF agents induced E-selectin expression, but only infliximab induced interleukin-10 production, apoptosis, and G0/G1 cell cycle arrest. Apoptosis and cell cycle arrest were abolished by substitution of all 3 cytoplasmic serine residues of mTNF by alanine residues. Infliximab induced accumulation of reactive oxygen species and up-regulation of Bax, Bak, and p21WAF1/CIP1 proteins, suggesting the involvement of p53 activation. Moreover, phosphorylation of c-Jun NH2-terminal kinase was necessary for infliximab-induced apoptosis and cell cycle arrest. Conclusions: We revealed the mTNF motifs and the downstream intracellular molecular events essential for reverse signaling through mTNF. The biologic effects of mTNF elicited by infliximab should be important action mechanisms of this potent anti-inflammatory agent in addition to the neutralization of soluble TNF-α. These observations will provide insight into the novel role of mTNF in inflammation.

UR - http://www.scopus.com/inward/record.url?scp=14944382276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944382276&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2004.11.060

DO - 10.1053/j.gastro.2004.11.060

M3 - Article

C2 - 15685549

AN - SCOPUS:14944382276

VL - 128

SP - 376

EP - 392

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -